- Home
- PSTV vs PHGE Comparison
PSTV vs PHGE Comparison
Compare PSTV & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTV
- PHGE
- Stock Information
- Founded
- PSTV 1996
- PHGE 2015
- Country
- PSTV United States
- PHGE Israel
- Employees
- PSTV N/A
- PHGE N/A
- Industry
- PSTV Medical/Dental Instruments
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- PSTV Health Care
- PHGE Health Care
- Exchange
- PSTV Nasdaq
- PHGE Nasdaq
- Market Cap
- PSTV 17.0M
- PHGE 15.5M
- IPO Year
- PSTV N/A
- PHGE N/A
- Fundamental
- Price
- PSTV $0.68
- PHGE N/A
- Analyst Decision
- PSTV Strong Buy
- PHGE Strong Buy
- Analyst Count
- PSTV 4
- PHGE 1
- Target Price
- PSTV $8.00
- PHGE $15.00
- AVG Volume (30 Days)
- PSTV 45.5M
- PHGE 380.3K
- Earning Date
- PSTV 11-13-2025
- PHGE 11-13-2025
- Dividend Yield
- PSTV N/A
- PHGE N/A
- EPS Growth
- PSTV N/A
- PHGE N/A
- EPS
- PSTV N/A
- PHGE N/A
- Revenue
- PSTV $5,317,000.00
- PHGE N/A
- Revenue This Year
- PSTV $28.09
- PHGE N/A
- Revenue Next Year
- PSTV N/A
- PHGE N/A
- P/E Ratio
- PSTV N/A
- PHGE N/A
- Revenue Growth
- PSTV N/A
- PHGE N/A
- 52 Week Low
- PSTV $0.16
- PHGE $0.34
- 52 Week High
- PSTV $2.31
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- PSTV 53.45
- PHGE 64.60
- Support Level
- PSTV $0.64
- PHGE $0.57
- Resistance Level
- PSTV $0.71
- PHGE $0.65
- Average True Range (ATR)
- PSTV 0.10
- PHGE 0.04
- MACD
- PSTV -0.00
- PHGE 0.01
- Stochastic Oscillator
- PSTV 24.45
- PHGE 87.23
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).